Literature DB >> 9808553

Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party.

E Carreras1, H Bertz, W Arcese, J P Vernant, J F Tomás, H Hagglund, G Bandini, H Esperou, J Russell, J de la Rubia, G Di Girolamo, H Demuynck, O Hartmann, J Clausen, T Ruutu, V Leblond, A Iriondo, A Bosi, I Ben-Bassat, V Koza, A Gratwohl, J F Apperley.   

Abstract

To determine the incidence and outcome of hepatic veno-occlusive disease (VOD) after blood or marrow transplantation (BMT), we prospectively evaluated all consecutive patients receiving a BMT during a 6-month period in participating EBMT centers. All of them were evaluated for occurrence of VOD according to previously defined clinical criteria. The clinical course, outcome, value of prophylactic and therapeutic interventions, and the influence of previously described risk factors were analyzed. During the study period, 1,652 BMT were performed in 73 centers. VOD was diagnosed in 87 patients (5.3%; 95% confidence interval [CI], 4.2% to 6.4%). Fifty-six of 631 allogeneic BMT (8.9%) and 31 of 1,010 autologous BMT (3.1%) developed this complication (P <.0001). VOD was classified as mild in 7 (8%), moderate in 56 (64.4%), and severe in 24 (27.6%) cases. Sixteen patients died of VOD (corresponding to 1% of the whole series, 18.4% of VOD patients, and 66.7% of severe VOD). The use of unfractionated heparin did not significantly decrease the incidence of VOD. Independent variables associated with an increased risk of VOD were allogeneic BMT (relative risk [RR], 2.8; P <.001), pre-BMT elevation of serum aspartate aminotransferase (RR, 2.4; P =.001), high-dose cytoreductive therapy (RR, 2.3; P =.003), Karnofsky performance score less than 90% (RR, 2.7; P =.006), and prior abdominal radiation (RR, 2.9; P =.03). In conclusion, this prospective study shows that (1) the incidence of VOD is lower than that reported in smaller studies from single centers, (2) about one fourth of cases of VOD progress to severe disease, (3) main risk factors have a major impact on incidence of VOD, and (4) the use of prophylactic unfractionated heparin does not seem to reduce the incidence of VOD.

Entities:  

Mesh:

Year:  1998        PMID: 9808553

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  75 in total

Review 1.  [Thrombophilic states in intensive care medicine].

Authors:  L Engelmann
Journal:  Med Klin Intensivmed Notfmed       Date:  2011-10-28       Impact factor: 0.840

2.  Irradiation induces homing of donor endothelial progenitor cells in allogeneic hematopoietic stem cell transplantation.

Authors:  Lingyu Zeng; Shuang Ding; Zhiling Yan; Chong Chen; Wei Sang; Jiang Cao; Hai Cheng; Kailin Xu
Journal:  Int J Hematol       Date:  2012-01-19       Impact factor: 2.490

3.  The role of gemtuzumab ozogamicin in combination chemotherapy regimens for primary resistant or relapsed acute myeloid leukemia.

Authors:  Hien K Duong; Matt Kalaycio
Journal:  Curr Hematol Malig Rep       Date:  2009-04       Impact factor: 3.952

Review 4.  Acute kidney injury in HCT: an update.

Authors:  J A Lopes; S Jorge; M Neves
Journal:  Bone Marrow Transplant       Date:  2016-02-08       Impact factor: 5.483

5.  Escalation to High-Dose Defibrotide in Patients with Hepatic Veno-Occlusive Disease.

Authors:  Brandon M Triplett; Hani I Kuttab; Guolian Kang; Wing Leung
Journal:  Biol Blood Marrow Transplant       Date:  2015-08-14       Impact factor: 5.742

6.  The busulfan metabolite EdAG irreversibly glutathionylates glutaredoxins.

Authors:  Michele Scian; William M Atkins
Journal:  Arch Biochem Biophys       Date:  2015-08-14       Impact factor: 4.013

7.  Antineoplastic agent busulfan regulates a network of genes related to coagulation and fibrinolysis.

Authors:  Janka Reimer; Sandra Bien; Sabine Ameling; Elke Hammer; Uwe Völker; Georg Hempel; Joachim Boos; Heyo K Kroemer; Christoph A Ritter
Journal:  Eur J Clin Pharmacol       Date:  2012-06       Impact factor: 2.953

8.  Clinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplant.

Authors:  Rish K Pai; Koen van Besien; John Hart; Andrew S Artz; Peter H O'Donnell
Journal:  Leuk Lymphoma       Date:  2012-03-13

Review 9.  Vascular liver diseases.

Authors:  Laurie D DeLeve
Journal:  Curr Gastroenterol Rep       Date:  2003-02

10.  A phase II study of intensified chemotherapy alone as initial treatment for newly diagnosed anaplastic oligodendroglioma: an interim analysis.

Authors:  Nimish A Mohile; Peter Forsyth; Douglas Stewart; Jeffrey J Raizer; Nina Paleologos; Tarun Kewalramani; David N Louis; J Gregory Cairncross; Lauren E Abrey
Journal:  J Neurooncol       Date:  2008-05-06       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.